Tenderwize
Retour à la recherche

Open House Drug Discount Agreements Brinzolamid and Brimonidin, ATC S01EC24

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Feb 05, 2027 · 160 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Brinzolamid und Brimonidin, ATC S01EC24

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

20 / 100

Facteurs de risque

No guaranteed minimum volume or sales; agreements are non-exclusive and can be overridden by other discount contracts.

Strict submission rules: paper documents require two original copies, and electronic submissions require qualified elec...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Mar 2027
  • Non-exclusive pharmaceutical rebate agreements for Brinzolamid and Brimonidin (ATC S01EC24)
  • Agreements are identical and non-negotiable
Afficher le résumé complet

This is an open-house model for non-exclusive rebate agreements for the active substances Brinzolamid and Brimonidin (ATC S01EC24) with AOK Bayern. It is not a standard procurement procedure; any qualified pharmaceutical company can enter into identical, non-negotiable agreements. The contract runs from April 1, 2025 to March 31, 2027, with possible entry anytime until February 5, 2027.

Risques

No guaranteed minimum volume or sales; agreements are non-exclusive and can be overridden by other discount contracts.

Strict submission rules: paper documents require two original copies, and electronic submissions require qualified elec...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Only pharmaceutical companies may participate

Administrative

  • Submit signed self-declaration of reliability
  • Submit signed contract and annex listing the specific drugs

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

Eligibility based on self-declaration of reliability; no competitive award criteria.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open House Drug Discount Agreements Brinzolamid and Brimonidin, ATC S01EC24

Non-exclusive rebate agreements for the specified active substances, open to all qualified pharmaceutical companies.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Mar 2025 - Mar 2027

Catégorie

Pharmaceutical products

Critères d'attribution

Eligibility based on self-declaration of reliability; no competitive award criteria.

Date limite

Deadline Feb 05, 2027

Détails de la procédure

Date de publication
17 Feb 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
106957-2025

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30